The Procalcitonin And Survival Study (PASS) – A Randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker <it>Procalcitonin </it>and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients

The Procalcitonin And Survival Study (PASS) – A Randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker <it>Procalcitonin </it>and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients

<p>Abstract</p> <p>Background</p> <p>Sepsis and complications to sepsis are major causes of mortality in critically ill patients. Rapid treatment of sepsis is of crucial importance for survival of patients. The infectious status of the critically ill patient is often di...

Full description

Bibliographic Details
Main Authors: Fjeldborg Paul, Andersen Mads H, Hestad Søren, Bestle Morten, Søe-Jensen Peter, Tousi Hamid, Petersen J Asger, Carl Peder, Steensen Morten, Løken Jesper, Thormar Katrin, Thornberg Klaus J, Bømler Bonnie, Hougaard Sine, Mantoni Teit, Lauritsen Anne Ø, Andersen Lasse H, Petersen Pernille L, Mohr Thomas, Hein Lars, Lundgren Bettina, Jensen Jens-Ulrik, Larsen Kim M, Rossau Charlotte, Thomsen Carsten B, Østergaard Christian, Kjær Jesper, Grarup Jesper, Lundgren Jens D
Format: Article
Language:English
Published: BMC 2008-07-01
Series:BMC Infectious Diseases
Online Access:http://www.biomedcentral.com/1471-2334/8/91

Internet

http://www.biomedcentral.com/1471-2334/8/91

Similar Items